Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.

AIMS A new oxycodone formulation (Reformulated OxyContin® was released in Australia, early 2014. It was developed as a tamper-resistant ('abuse-deterrent') formulation of the drug. We summarize methods used in the National Opioid Medication Abuse Deterrence (NOMAD) study, which will examine: (i) whether there is a reduction in extra-medical use (including via tampering) of OxyContin® following the introduction of Reformulated OxyContin®; (ii) potential changes in extra-medical use of non-abuse-deterrent forms of oxycodone, other pharmaceutical opioids and illicit drugs; (iii) whether methods of tampering with Reformulated OxyContin® become widespread over time; (iv) Reformulated OxyContin®'s attractiveness on the illicit market; and (v) sales, prescriptions and harms related to OxyContin® and other drugs. METHODS There are three major components. First, analyses of existing routine data sources such as: pharmaceutical sales; prescribing data; data on drug overdose deaths; and survey data on drug use in the general population and among people who inject drugs; secondly, specific data on OxyContin® collected through the Illicit Drug Reporting System; and thirdly, a prospective cohort of n = 606 people who regularly misuse or tamper with pharmaceutical opioids was formed prior to the introduction of Reformulated OxyContin®, followed-up twice post-release to examine potential changes after Reformulated OxyContin®'s introduction. DISCUSSION The study's strengths lie in varied data collections; interrupted time-series analysis; and prospective cohort. To our knowledge, this is one of the most comprehensive and transparently conducted studies conducted to date of the potential impact of an opioid medication upon use, tampering and diversion. Results have the potential to inform policymakers, clinicians, consumers and researchers alike.

[1]  J. Havens,et al.  The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. , 2014, Drug and alcohol dependence.

[2]  J. Davis,et al.  Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. , 2013, The journal of pain : official journal of the American Pain Society.

[3]  W. Hall,et al.  Estimating the proportion of prescription opioids that is consumed by people who inject drugs in Australia. , 2013, Drug and alcohol review.

[4]  E. Sellers,et al.  Update on tamper-resistant drug formulations. , 2013, Drug and alcohol dependence.

[5]  S. Butler,et al.  Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. , 2013, The journal of pain : official journal of the American Pain Society.

[6]  Raimondo Bruno,et al.  Prescription of opioid analgesics and related harms in Australia , 2011, The Medical journal of Australia.

[7]  Nathaniel Katz,et al.  Tampering with Prescription Opioids: Nature and Extent of the Problem, Health Consequences, and Solutions , 2011, The American journal of drug and alcohol abuse.

[8]  A. Winstock,et al.  Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours. , 2011, Drug and alcohol review.

[9]  S. Tregear,et al.  Long-term opioid management for chronic noncancer pain. , 2010, The Cochrane database of systematic reviews.

[10]  D. Juurlink,et al.  Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone , 2009, Canadian Medical Association Journal.

[11]  P. Haber,et al.  Examination of opioid prescribing in Australia from 1992 to 2007 , 2009, Internal medicine journal.

[12]  Nathaniel Katz.  Abuse-deterrent opioid formulations: Are they a pipe dream? , 2008, Current rheumatology reports.

[13]  J. Inciardi,et al.  Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States. , 2007, Drug and alcohol dependence.

[14]  M. Schuckit,et al.  Diagnostic Issues in Substance Use Disorders: Refining the Research Agenda for DSM-V , 2007 .

[15]  Fausto Mazzi,et al.  Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health Surveys , 2006, International journal of methods in psychiatric research.

[16]  R. Carlson,et al.  Initiation to Pharmaceutical Opioids and Patterns of Misuse: Preliminary Qualitative Findings Obtained by the Ohio Substance Abuse Monitoring Network , 2006 .

[17]  C. Treloar,et al.  Comparison of needle and syringe programme attendees and non-attendees from a high drug-using area in Sydney, New South Wales. , 2006, Drug and alcohol review.

[18]  Jeff Ward,et al.  Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. , 2006, Drug and alcohol review.

[19]  Yongli Xi,et al.  Increasing deaths from opioid analgesics in the United States , 2006, Pharmacoepidemiology and drug safety.

[20]  S. Gilmour,et al.  Identification and quantification of change in Australian illicit drug markets , 2006, BMC public health.

[21]  C. Schuster.  History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. , 2006, Drug and alcohol dependence.

[22]  P. Fudala,et al.  Development of opioid formulations with limited diversion and abuse potential. , 2006, Drug and alcohol dependence.

[23]  E. Cone.  Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. , 2006, Drug and alcohol dependence.

[24]  R. Griffiths,et al.  Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. , 2006, Drug and alcohol dependence.

[25]  N. Volkow,et al.  Abuse of prescription drugs and the risk of addiction. , 2006, Drug and alcohol dependence.

[26]  B. Löwe,et al.  A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.

[27]  L. Degenhardt,et al.  Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example , 2006, BMC Medical Research Methodology.

[28]  S. Butler,et al.  Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers , 2006, Harm reduction journal.

[29]  Nora D Volkow,et al.  Major increases in opioid analgesic abuse in the United States: concerns and strategies. , 2006, Drug and alcohol dependence.

[30]  A. Muñoz,et al.  Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. , 2005, The journal of pain : official journal of the American Pain Society.

[31]  W. Hall,et al.  The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. , 2005, Drug and alcohol dependence.

[32]  W. Hall,et al.  The effect of a reduction in heroin supply on fatal and non‐fatal drug overdoses in New South Wales, Australia , 2005, The Medical journal of Australia.

[33]  M. Jensen,et al.  Validation of the Brief Pain Inventory for chronic nonmalignant pain. , 2004, The journal of pain : official journal of the American Pain Society.

[34]  S. Skevington,et al.  The World Health Organization's WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A Report from the WHOQOL Group , 2004, Quality of Life Research.

[35]  R. Cummins,et al.  Developing a National Index of Subjective Wellbeing: The Australian Unity Wellbeing Index , 2003 .

[36]  R. Spitzer,et al.  The PHQ-9 , 2001, Journal of General Internal Medicine.

[37]  D. Kivlahan,et al.  The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. , 1998, Archives of internal medicine.

[38]  R. Day,et al.  Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users , 1997, Clinical pharmacokinetics.

[39]  B Powis,et al.  The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. , 1995, Addiction.

[40]  S. Fishman.  Surgery for leg numbness with back pain, patient controlled analgesia, phantom limb pain. , 2006, Journal of pain & palliative care pharmacotherapy.

[41]  O. Presslich,et al.  Combined naloxone/methadone preparations for opiate substitution therapy. , 1991, Journal of substance abuse treatment.